» Authors » Pierre Olivier

Pierre Olivier

Explore the profile of Pierre Olivier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 806
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Boursier C, Olivier P, Claudin M, Marie P, Imbert L
Clin Nucl Med . 2023 Sep; 48(10):e491-e493. PMID: 37682618
The tomoscintigraphy monitoring of 177Lu-prostate-specific membrane antigen (PSMA) treatment may be helpful for quality control and predicting therapeutic response. Furthermore, the drawbacks of relatively low image quality and extended recording...
2.
Oprea-Lager D, Gontier E, Garcia-Canamaque L, Gauthe M, Olivier P, Mitjavila M, et al.
Eur J Nucl Med Mol Imaging . 2023 Jun; 50(11):3439-3451. PMID: 37341747
Purpose: Primary objective was to compare the per-patient detection rates (DR) of [F]DCFPyL versus [F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT), in patients with first prostate cancer (PCa) biochemical recurrence (BCR)....
3.
Olivier P, Giraudet A, Skanjeti A, Merlin C, Weinmann P, Rudolph I, et al.
J Nucl Med . 2022 Nov; 64(4):579-585. PMID: 36418170
The objective of this study was to compare F-PSMA-1007 PET/CT and F-fluorocholine PET/CT for the localization of prostate cancer (PCa) biochemical recurrence. This prospective, open-label, randomized, crossover multicenter study included...
4.
Galtier J, Vercellino L, Chartier L, Olivier P, Tabouret-Viaud C, Mesguich C, et al.
Haematologica . 2022 Jun; 108(1):171-180. PMID: 35678029
The aim of this study was to evaluate the prognostic impact of the F-fluorodeoxyglucose positron emission tomography response at 1 month (M1) and 3 months (M3) after anti-CD19 chimeric antigen...
5.
Kortsch S, Frelat R, Pecuchet L, Olivier P, Putnis I, Bonsdorff E, et al.
J Anim Ecol . 2021 Feb; 90(5):1205-1216. PMID: 33608888
Studying how food web structure and function vary through time represents an opportunity to better comprehend and anticipate ecosystem changes. Yet, temporal studies of highly resolved food web structure are...
6.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, DAveni-Piney M, et al.
Blood Adv . 2020 Nov; 4(22):5607-5615. PMID: 33180899
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The...
7.
Salvadori J, Odille F, Verger A, Olivier P, Karcher G, Marie P, et al.
EJNMMI Phys . 2020 Feb; 7(1):11. PMID: 32086646
Background: Routine PET exams are increasingly performed with reduced injected activities, leading to the use of different image reconstruction parameters than the NEMA parameters, in order to prevent from any...
8.
Bernier M, Lancrerot S, Rocher F, Van-Obberghen E, Olivier P, Lavrut T, et al.
J Geriatr Cardiol . 2019 Dec; 16(11):806-811. PMID: 31853245
Background: The direct oral anticoagulant dabigatran does not require any routine therapeutic drug monitoring. Yet, concerns about possible drug interactions susceptible to increase its inherent bleeding risk, especially in very...
9.
Lovinfosse P, Rousseau C, Pierga J, Bouchet F, Cochet A, Alberini J, et al.
EJNMMI Res . 2019 Dec; 9(1):109. PMID: 31832803
Purpose: For differentiating tumor from inflammation and normal tissues, fluorodeoxyglucose ([F]FDG) dual time point PET could be helpful. Albeit [F]FLT is more specific for tumors than [F]FDG; we explored the...
10.
Raynal M, Bouderraoui F, Ouichka R, Melchior J, Morel O, Blum A, et al.
Arthritis Res Ther . 2019 May; 21(1):119. PMID: 31088514
Purpose: To assess increased sacroiliac joint (SIJ) uptake on F-NaF PET/CT and to compare with MRI for inflammation and with CT scan for structural damages in a population of 23...